Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating VX-371 for safety and efficacy in cystic fibrosis patients with F508del-CFTR mutation has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-371

Snippet

Sponsor: Parion Sciences | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2021-07-29